elderly Philadelphia chromosome/BCR-ABL1 positive acute lymphoblastic leukemia
Conditions
Interventions
Case series:Flumatinib combined with chemotherapy
Sponsors
Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: Male or female patients aged 65-80years; Patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia; Patients without serious heart disease or coronary heart disease history; Patients with liver and kidney function suitable for chemotherapy: SGOT and SGPT should not exceed 2 times of the upper limit of normal; amylase and lipase in serum should not exceed 2 times of the upper limit of normal; total bilirubin in serum should not exceed 3 times of the upper limit of normal; Patients willing to sign informed consent.
Exclusion criteria
Exclusion criteria: History of other cancers, except basal cell carcinoma; with contraindications of corticosteroids; diabetes which cannot be successfully controlled; HIV and syphilis-infected patients; patients previously received an organ transplantation; severe neurological or psychiatric history.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 year-relapse free survival;progression free survival;minimal residual disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete remission;overall survival;safety;mutation rate of Abl kinase domain; | — |
Countries
China
Contacts
Public ContactJin Wang
Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of medicine
Outcome results
None listed